mRNA COVID Vaccine Dosing Intervals May Be Extended To Mitigate Myocarditis Risk

The US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices supports extending the interval between the first and second doses of mRNA COVID-19 vaccines to eight weeks in order to mitigate the risk of myocarditis.

The committee did not vote on whether to change the dosing interval, but members agreed that it would be beneficial. The sole vote at ACIP’s 4 February meeting was on whether to recommend Moderna, Inc.’s COVID-19 vaccine Spikevax for persons 18 years of age and older following the US Food and Drug Administration’s full approval of the vaccine on 31 January